Η ενδοκυττάρια οδός μετακίνησης του EGFR στον καρκίνο του παχέος εντέρου
Περίληψη
Όλα τα τεκμήρια στο ΕΑΔΔ προστατεύονται από πνευματικά δικαιώματα.
Περίληψη σε άλλη γλώσσα
Autophagy has been identified as a catabolic mechanism in cells but its' role in cancer remains controversial. Autophagy has been characterized either as tumor suppressor or inducer mechanism in many tumor types. Monoclonal antibodies against EGFR (cetuximab and panitumumab) represent a major step in the treatment of mCRC. Several studies propose that cetuximab and panitumumab trigger autophagy which reveals a potential resistance mechanism to these agents. The last few years immunotherapy appears to be a novel promising strategy for the treatment of patients with solid tumors, including colorectal cancer. Checkpoint inhibitors, such as anti-PD1 (Nivolumab and Pembrolizumab) and anti-CTLA-4 (Ipilimumab) antibodies have already been developed and applied in mCRC patients with MSI-H phenotype. The association between mtBRAF and autophagy or MSI status has already been characterized. In our study, we identify the autophagy initiation through anti-EGFR monoclonal antibodies and checkpoint ...
περισσότερα
![]() | |
![]() | Κατεβάστε τη διατριβή σε μορφή PDF (9.08 MB)
(Η υπηρεσία είναι διαθέσιμη μετά από δωρεάν εγγραφή)
|
Όλα τα τεκμήρια στο ΕΑΔΔ προστατεύονται από πνευματικά δικαιώματα.
|